ViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and Progress Towards Product Registration in India
ViaDerma (OTC Pink: VDRM) has announced the opening of a satellite office in Dubai to support its Middle Eastern expansion, complying with local regulations requiring physical presence for commercial operations. The company also reports progress in India, where it recently met with officials from a large that works closely with the Indian government. ViaDerma's registration application for its topical antibiotic solution in India is in its final stages, with approval expected in Q1 2025.
The potential market entry into India, with its population of approximately 1.4 billion people, represents a significant opportunity for ViaDerma's topical antibiotic products. The company's CEO, Dr. Christopher Otiko, expressed confidence in breakout growth for 2025, building on the company's 2024 achievements.
ViaDerma (OTC Pink: VDRM) ha annunciato l'apertura di un ufficio satellite a Dubai per supportare la sua espansione nel Medio Oriente, conformandosi alle normative locali che richiedono una presenza fisica per le operazioni commerciali. L'azienda riferisce anche progressi in India, dove ha recentemente incontrato funzionari di un'importante organizzazione che collabora strettamente con il governo indiano. La domanda di registrazione di ViaDerma per la sua soluzione antibiotica topica in India è nelle fasi finali, con approvazione prevista per il primo trimestre del 2025.
L'ingresso potenziale nel mercato indiano, con una popolazione di circa 1,4 miliardi di persone, rappresenta un'opportunità significativa per i prodotti antibiotici topici di ViaDerma. Il CEO dell'azienda, Dr. Christopher Otiko, ha espresso fiducia in una crescita significativa nel 2025, basandosi sui risultati del 2024.
ViaDerma (OTC Pink: VDRM) ha anunciado la apertura de una oficina satélite en Dubái para apoyar su expansión en Oriente Medio, cumpliendo con las regulaciones locales que exigen una presencia física para operaciones comerciales. La compañía también informa sobre avances en India, donde se reunió recientemente con funcionarios de una gran organización que trabaja estrechamente con el gobierno indio. La solicitud de registro de ViaDerma para su solución antibiótica tópica en India está en sus etapas finales, con aprobación esperada para el primer trimestre de 2025.
La posible entrada en el mercado indio, con una población de aproximadamente 1,4 mil millones de personas, representa una oportunidad significativa para los productos antibióticos tópicos de ViaDerma. El CEO de la compañía, Dr. Christopher Otiko, expresó confianza en un crecimiento explosivo para 2025, basándose en los logros de la compañía en 2024.
ViaDerma (OTC Pink: VDRM)은 중동 지역 확장을 지원하기 위해 두바이에 위성 사무소를 개설했다고 발표하며, 상업 운영을 위한 물리적 존재를 요구하는 현지 규정을 준수하고 있습니다. 이 회사는 또한 인도에서의 진전을 보고하며, 최근 인도 정부와 밀접하게 협력하는 대규모 기관의 관계자들과 만났습니다. ViaDerma의 인도에서의 국소 항생제 솔루션 등록 신청은 최종 단계에 있으며, 2025년 1분기에 승인이 예상됩니다.
약 14억 명의 인구를 가진 인도 시장 진입 가능성은 ViaDerma의 국소 항생제 제품에 대한 중요한 기회를 나타냅니다. 회사의 CEO인 Dr. Christopher Otiko는 2024년의 성과를 바탕으로 2025년에 급격한 성장이 있을 것이라고 확신했습니다.
ViaDerma (OTC Pink: VDRM) a annoncé l'ouverture d'un bureau satellite à Dubaï pour soutenir son expansion au Moyen-Orient, en conformité avec les réglementations locales exigeant une présence physique pour les opérations commerciales. L'entreprise rapporte également des progrès en Inde, où elle a récemment rencontré des responsables d'une grande organisation qui collabore étroitement avec le gouvernement indien. La demande d'enregistrement de ViaDerma pour sa solution antibiotique topique en Inde est dans sa phase finale, avec une approbation attendue au premier trimestre 2025.
L'entrée potentielle sur le marché indien, avec une population d'environ 1,4 milliard de personnes, représente une opportunité significative pour les produits antibiotiques topiques de ViaDerma. Le PDG de l'entreprise, Dr. Christopher Otiko, a exprimé sa confiance dans une forte croissance pour 2025, s'appuyant sur les réalisations de l'entreprise en 2024.
ViaDerma (OTC Pink: VDRM) hat die Eröffnung eines Satellitenbüros in Dubai angekündigt, um seine Expansion im Nahen Osten zu unterstützen und den lokalen Vorschriften nachzukommen, die eine physische Präsenz für kommerzielle Aktivitäten erfordern. Das Unternehmen berichtet auch von Fortschritten in Indien, wo es kürzlich mit Beamten einer großen Organisation zusammentraf, die eng mit der indischen Regierung zusammenarbeitet. Der Registrierungsantrag von ViaDerma für seine topische antibiotische Lösung in Indien befindet sich in der finalen Phase, mit einer Genehmigung, die für das erste Quartal 2025 erwartet wird.
Der potenzielle Markteintritt in Indien, mit einer Bevölkerung von etwa 1,4 Milliarden Menschen, stellt eine bedeutende Gelegenheit für die topischen Antibiotikaprodukte von ViaDerma dar. Der CEO des Unternehmens, Dr. Christopher Otiko, äußerte Zuversicht in ein starkes Wachstum für 2025, basierend auf den Erfolgen des Unternehmens im Jahr 2024.
- Expansion into Dubai market with new satellite office establishment
- Final stages of product registration approval in India expected in Q1 2025
- Potential access to India's 1.4 billion population market
- Progress in discussions with large Indian with government connections
- None.
LOS ANGELES, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, is pleased to announce the opening of a satellite office in Dubai to facilitate its ongoing expansion in the Middle East. Local regulations require businesses to maintain a physical office within the region to conduct commercial operations, making this a strategic move to further ViaDerma's growth and accessibility in the market.
In addition to its Middle Eastern expansion, ViaDerma recently had a productive meeting in Los Angeles with visiting officials from a large corporation based in India, which conducts extensive business with the Indian government. With a population of approximately 1.4 billion people, India presents significant market potential for ViaDerma's topical antibiotic solution. The meeting focused on potential business collaborations in anticipation of ViaDerma receiving final approval for the registration of its topical antibiotic solution in India. The registration application process which began several months ago is now in the final stages, with approval expected in the first quarter of this year.
Dr. Christopher Otiko, CEO of ViaDerma, Inc., stated, "Our accomplishments in 2024 have laid a strong foundation for the breakout growth we anticipate in 2025 as we continue to build on these advancements and explore new opportunities worldwide."
ViaDerma remains committed to enhancing global access to its advanced topical antibiotic solutions and continues to explore opportunities for strategic partnerships and market entry worldwide.
About ViaDerma, Inc.
ViaDerma, Inc. (OTC Pink: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative transdermal drug delivery technology solutions to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, please visit: https://viaderma.com.
Any forecast of future performance is a "forward-looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
Contact information:
Investor Relations
Email: ir@viaderma.com
Phone: 310-734-6111
FAQ
When is ViaDerma (VDRM) expecting approval for its product registration in India?
Why did ViaDerma (VDRM) open a satellite office in Dubai?
What is the market potential for ViaDerma (VDRM) in India?
What are ViaDerma's (VDRM) expansion plans for 2025?
